Publicaciones en colaboración con investigadores/as de Instituto de Química Orgánica General (23)

2024

  1. Design and Synthesis of Multi-Functional Ligands through Hantzsch Reaction: Targeting Ca2+ Channels, Activating Nrf2 and Possessing Cathepsin S Inhibitory, and Antioxidant Properties

    Pharmaceutics, Vol. 16, Núm. 1

  2. In Vitro Modulation of Autophagy by New Antioxidant Nitrones as a Potential Therapeutic Approach for the Treatment of Ischemic Stroke

    Antioxidants, Vol. 13, Núm. 8

2021

  1. Use of Radical Oxygen Species Scavenger Nitrones to Treat Oxidative Stress-Mediated Hearing Loss: State of the Art and Challenges

    Frontiers in Cellular Neuroscience, Vol. 15

2020

  1. Tacrine-natural-product hybrids for alzheimer’s disease therapy

    Current Medicinal Chemistry, Vol. 27, Núm. 26, pp. 4392-4400

2019

  1. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 479-489

  2. Synthesis and Neuroprotective Properties of N-Substituted C-Dialkoxyphosphorylated Nitrones

    ACS Omega, Vol. 4, Núm. 5, pp. 8581-8587

  3. Synthesis of new ferulic/lipoic/comenic acid-melatonin hybrids as antioxidants and Nrf2 activators via Ugi reaction

    Future Medicinal Chemistry, Vol. 11, Núm. 24, pp. 3097-3108

  4. Synthesis, antioxidant and Aβ anti-aggregation properties of new ferulic, caffeic and lipoic acid derivatives obtained by the Ugi four-component reaction

    Bioorganic Chemistry, Vol. 85, pp. 221-228

  5. Synthesis, neuroprotective and antioxidant capacity of PBN-related indanonitrones

    Bioorganic Chemistry, Vol. 86, pp. 445-451

2018

  1. Alzheimer's Disease, the "one-Molecule, One-Target" Paradigm, and the Multitarget Directed Ligand Approach

    ACS Chemical Neuroscience, Vol. 9, Núm. 3, pp. 401-403

2017

  1. Corrigendum: Melatonin and nitrones as potential therapeutic agents for stroke [Front. Aging Neurosci., 8 (2016) (281)] DOI:10.3389/fnagi.2016.00281

    Frontiers in Aging Neuroscience

  2. New tacrines as anti-alzheimer’s disease agents. The (benzo)chromeno-pyranotacrines

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 31, pp. 3349-3360

2016

  1. Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 122, pp. 326-338

  2. Melatonin and nitrones as potential therapeutic agents for stroke

    Frontiers in Aging Neuroscience, Vol. 8, Núm. NOV

  3. Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 118, pp. 178-192

2015

  1. Pyranopyrazolotacrines as nonneurotoxic, Aβ-anti-aggregating and neuroprotective agents for Alzheimer's disease

    Future Medicinal Chemistry, Vol. 7, Núm. 7, pp. 845-855

2014

  1. Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9, 10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 74, pp. 491-501

2013

  1. Nontoxic and neuroprotective β-naphthotacrines for alzheimer's disease

    Chemical Research in Toxicology, Vol. 26, Núm. 6, pp. 986-992

  2. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease

    Bioorganic and Medicinal Chemistry Letters, Vol. 23, Núm. 7, pp. 1916-1922

2012

  1. Drugs for stroke: Action of nitrone (Z)-N-(2-bromo-5-hydroxy-4- methoxybenzylidene)-2-methylpropan-2-amine oxide on rat cortical neurons in culture subjected to oxygen-glucose-deprivation

    European Journal of Medicinal Chemistry, Vol. 55, pp. 475-479